VBI Vaccines (NASDAQ:VBIV) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a report issued on Saturday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

VBI Vaccines Trading Up 1.3 %

Shares of VBI Vaccines stock traded up $0.01 during midday trading on Friday, hitting $0.59. The company had a trading volume of 165,340 shares, compared to its average volume of 729,607. VBI Vaccines has a 1-year low of $0.45 and a 1-year high of $3.47. The business’s 50 day simple moving average is $0.61 and its two-hundred day simple moving average is $0.61.

About VBI Vaccines

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.